Neoplasm Trials in Boston, United States
Conditions / Neoplasm / Boston, United States
Neoplasm is a medical condition with active clinical research programs worldwide.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03251924 | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | TERMINATED | PHASE1/PHASE2 |
| NCT03637764 | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | TERMINATED | PHASE1/PHASE2 |
| NCT01920061 | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | COMPLETED | PHASE1 |
| NCT00083720 | Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy | COMPLETED | PHASE2 |
| NCT00408434 | Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer | COMPLETED | PHASE1 |
| NCT03415126 | A Study of ASN007 in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 |
| NCT06759649 | A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies | RECRUITING | PHASE1 |
| NCT00657254 | Extension Program for Bay 43-9006 | COMPLETED | PHASE2 |
| NCT02473497 | Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients | NO_LONGER_AVAILABLE | — |
| NCT00034879 | Iressa Expanded Access Program (EAP) | COMPLETED | PHASE3 |